End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.59 CNY | +4.03% | +5.58% | -2.22% |
Apr. 26 | Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 29 | Dongbao Pharma's 2023 Profit Drops 26% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- Based on current prices, the company has particularly high valuation levels.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.22% | 2.9B | C | ||
-4.66% | 86.13B | A- | ||
+1.32% | 39.82B | A- | ||
-19.27% | 30.42B | B- | ||
+57.86% | 25.23B | A | ||
-16.09% | 15.36B | C | ||
-9.14% | 11.95B | D+ | ||
-17.69% | 11.6B | B- | ||
-43.00% | 11.51B | B | ||
+5.24% | 8.71B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600867 Stock
- Ratings Tonghua Dongbao Pharmaceutical Co., Ltd.